CryoPort, Inc. (NASDAQ:CYRX) had its price objective hoisted by research analysts at Needham & Company LLC from $6.00 to $8.50 in a report released on Wednesday, July 26th, MarketBeat.com reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s price target indicates a potential upside of 17.73% from the company’s current price.
Several other equities research analysts have also recently commented on the stock. Janney Montgomery Scott initiated coverage on shares of CryoPort in a research report on Wednesday, July 12th. They issued a “buy” rating and a $8.00 target price for the company. ValuEngine upgraded shares of CryoPort from a “sell” rating to a “hold” rating in a research note on Thursday, May 11th. Finally, Cowen and Company assumed coverage on shares of CryoPort in a research note on Friday, June 16th. They issued an “outperform” rating and a $5.50 price target for the company.
Shares of CryoPort (NASDAQ:CYRX) opened at 7.22 on Wednesday. CryoPort has a 1-year low of $1.80 and a 1-year high of $7.40. The firm has a 50-day moving average of $5.83 and a 200 day moving average of $3.86. The company’s market capitalization is $173.03 million.
CryoPort (NASDAQ:CYRX) last posted its earnings results on Tuesday, August 8th. The company reported ($0.08) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.09) by $0.01. CryoPort had a negative net margin of 102.89% and a negative return on equity of 67.75%. The firm had revenue of $2.92 million during the quarter, compared to analysts’ expectations of $2.84 million. On average, equities research analysts expect that CryoPort will post ($0.72) earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This piece of content was originally published by BNB Daily and is the property of of BNB Daily. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://www.baseball-news-blog.com/2017/08/13/cryoport-inc-cyrx-pt-raised-to-8-50-2-updated-updated.html.
A number of hedge funds have recently added to or reduced their stakes in the stock. Northern Trust Corp raised its stake in CryoPort by 105.0% in the second quarter. Northern Trust Corp now owns 22,179 shares of the company’s stock worth $109,000 after buying an additional 11,358 shares in the last quarter. BerganKDV Wealth Management LLC raised its stake in shares of CryoPort by 157.5% in the second quarter. BerganKDV Wealth Management LLC now owns 25,750 shares of the company’s stock worth $127,000 after buying an additional 15,750 shares in the last quarter. EAM Investors LLC bought a new stake in shares of CryoPort during the second quarter worth approximately $552,000. D.A. Davidson & CO. raised its stake in shares of CryoPort by 16.6% in the second quarter. D.A. Davidson & CO. now owns 137,000 shares of the company’s stock worth $674,000 after buying an additional 19,500 shares in the last quarter. Finally, Taylor Wealth Management Partners bought a new stake in shares of CryoPort during the second quarter worth approximately $1,851,000. Institutional investors and hedge funds own 10.57% of the company’s stock.
CryoPort Company Profile
Cryoport, Inc (Cryoport) is a provider of cryogenic logistics solutions to the life sciences industry through its purpose-built packaging, information technology and specialized cold chain logistics expertise. The Company provides logistics solutions for biologic materials, such as immunotherapies, stem cells, chimeric antigen receptors (CAR)-T cells, and reproductive cells for clients.
Receive News & Ratings for CryoPort Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort Inc. and related companies with MarketBeat.com's FREE daily email newsletter.